Clinical trial · Observational
CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in Relapsed/Refractory Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this retrospective study is to compare between the case cohort and control cohort. The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate. The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care The main question\[s\] it aims to answer are: * Survival times * Response outcomes
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy | Drug | Immunotherapy | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- T cell engager
- interventionNames
- Drug: Immunotherapy
- label
- Standard-of-care
- interventionNames
- Drug: Immunotherapy
Primary outcomes (1)
- measure
- Comparison of Survival Periods Among Groups Comparison of Survival Periods Among Groups
- timeFrame
- Time Frame: Up to 2 years
- description
- overall survival
Secondary outcomes (1)
- measure
- Comparison of Progression-Free Survival Periods
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023. 2. Age 19 or older. 3. Anti-cancer salvage chemotherpay for the treatment of relapsed/refractory lymphoma. Exclusion Criteria: 1. Patients suffering from acute leukemia. 2. Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
References
Publications (0)
Data not yet available